August J. Troendle Insider Information
Dr. Troendle has been the Chief Executive Officer and Chairman of the Board of Directors of Medpace since he founded the Company in July 1992. Dr. Troendle was also the President of Medpace through July 31, 2021. Before founding Medpace, Dr. Troendle served as Assistant Director, Associate Director and Senior Associate Director from 1987 to 1992 at Sandoz (Novartis), where he was responsible for the clinical development of lipid altering agents. From 1986 to 1987, Dr. Troendle worked as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA. Dr. Troendle also has extensive experience serving as a director for a diverse group of public and private companies, including as a director of Coherus BioSciences, Inc. from 2012 to February 2018, as a director of Xenon Pharmaceuticals Inc. from 2007 to 2008, as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015. Dr. Troendle received his Medical Degree from the University of Maryland, School of Medicine.
What is August J. Troendle's net worth?
The estimated net worth of August J. Troendle is at least $998.74 million as of July 18th, 2022. Dr. Troendle owns 5,513,639 shares of Medpace stock worth more than $998,740,568 as of August 15th. This net worth approximation does not reflect any other investments that Dr. Troendle may own. Additionally, Dr. Troendle receives an annual salary of $1,540,000.00 as CEO at Medpace. Learn More about August J. Troendle's net worth.
How old is August J. Troendle?
What is August J. Troendle's salary?
As the CEO of Medpace Holdings, Inc., Dr. Troendle earned a total compensation package of $5,947,423.00 in 2021. Dr. Troendle earned a salary of $696,667.00, a bonus of $711,000.00, options awards of $4,409,925.00, and other compensation of $129,831.00. Learn More on August J. Troendle's salary.
How do I contact August J. Troendle?
Has August J. Troendle been buying or selling shares of Medpace?
During the last ninety days, August J. Troendle has bought $4,430,761.10 in shares of Medpace stock. Most recently, on Monday, July 18th, August J. Troendle bought 8,330 shares of Medpace stock. The stock was acquired at an average cost of $145.00 per share, with a total value of $1,207,850.00. Following the completion of the transaction, the chief executive officer now directly owns 5,513,639 shares of the company's stock, valued at $799,477,655. Learn More on August J. Troendle's trading history.
Who are Medpace's active insiders?
Are insiders buying or selling shares of Medpace?
In the last twelve months, Medpace insiders bought shares 2 times. They purchased a total of 30,620 shares worth more than $4,430,761.10. In the last twelve months, insiders at the sold shares 27 times. They sold a total of 365,104 shares worth more than $78,048,682.04. The most recent insider tranaction occured on July, 18th when CEO August J Troendle bought 8,330 shares worth more than $1,207,850.00. Insiders at Medpace own 20.6 % of the company.
Learn More about insider trades at Medpace. Information on this page was last updated on 7/18/2022.
August J. Troendle Insider Trading History at Medpace
| Transaction Date | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/18/2022 | Buy | 8,330 | $145.00 | $1,207,850.00 | 5,513,639 |  |
| 7/14/2022 | Buy | 22,290 | $144.59 | $3,222,911.10 | 5,505,309 | |
| 1/4/2022 | Sell | 3,338 | $213.44 | $712,462.72 | | |
| 12/29/2021 | Sell | 16,750 | $220.16 | $3,687,680.00 | | |
| 12/27/2021 | Sell | 39,171 | $226.11 | $8,856,954.81 | | |
| 12/22/2021 | Sell | 38,960 | $220.50 | $8,590,680.00 | | |
| 12/20/2021 | Sell | 22,734 | $212.57 | $4,832,566.38 | | |
| 12/17/2021 | Sell | 30,605 | $213.59 | $6,536,921.95 | | |
| 12/15/2021 | Sell | 2,424 | $210.28 | $509,718.72 | | |
| 12/9/2021 | Sell | 14,994 | $212.13 | $3,180,677.22 | | |
| 12/7/2021 | Sell | 18,520 | $211.78 | $3,922,165.60 | | |
| 11/29/2021 | Sell | 12,115 | $212.10 | $2,569,591.50 | | |
| 11/26/2021 | Sell | 15,071 | $210.99 | $3,179,830.29 | | |
| 11/24/2021 | Sell | 14,578 | $213.26 | $3,108,904.28 | | |
| 8/31/2021 | Sell | 12,675 | $182.04 | $2,307,357.00 | 706,643 | |
| 8/5/2021 | Sell | 556 | $180.04 | $100,102.24 | | |
| 7/26/2021 | Sell | 15,209 | $181.47 | $2,759,977.23 | | |
| 7/23/2021 | Sell | 18,882 | $181.21 | $3,421,607.22 | | |
| 7/21/2021 | Sell | 9,206 | $182.42 | $1,679,358.52 | 706,643 | |
| 7/19/2021 | Sell | 1,442 | $181.11 | $261,160.62 | 6,138,961 | |
| 7/15/2021 | Sell | 13,697 | $181.88 | $2,491,210.36 | | |
| 7/13/2021 | Sell | 13,050 | $182.96 | $2,387,628.00 | 706,643 | |
| 7/9/2021 | Sell | 12,597 | $183.34 | $2,309,533.98 | | |
| 7/7/2021 | Sell | 4,574 | $180.33 | $824,829.42 | 706,643 | |
| 6/29/2021 | Sell | 4,926 | $181.11 | $892,147.86 | 706,643 | |
| 6/23/2021 | Sell | 1,837 | $180.79 | $332,111.23 | 706,643 | |
| 6/21/2021 | Sell | 9,345 | $181.86 | $1,699,481.70 | 706,643 | |
| 6/18/2021 | Sell | 1,261 | $180.43 | $227,522.23 | 706,643 | |
| 6/16/2021 | Sell | 17,413 | $181.13 | $3,154,016.69 | 706,643 | |
| 4/22/2021 | Sell | 14,377 | $188.64 | $2,712,077.28 | 706,643 | |
| 4/20/2021 | Sell | 17,623 | $182.44 | $3,215,140.12 | 706,643 | |
| 4/16/2021 | Sell | 17,528 | $180.30 | $3,160,298.40 | 706,643 | |
| 4/14/2021 | Sell | 3,720 | $180.48 | $671,385.60 | 706,643 | |
| 1/7/2021 | Sell | 185,219 | $140.06 | $25,941,773.14 | 706,643 | |
| 12/30/2020 | Sell | 19,930 | $140.01 | $2,790,399.30 | 706,643 | |
| 12/28/2020 | Sell | 1,374 | $140.00 | $192,360.00 | 706,643 | |
| 12/23/2020 | Sell | 3,547 | $140.11 | $496,970.17 | 706,643 | |
| 12/18/2020 | Sell | 216,048 | $141.85 | $30,646,408.80 | 666,643 | |
| 8/24/2020 | Sell | 18,903 | $123.36 | $2,331,874.08 | 616,643 | |
| 8/19/2020 | Sell | 21,614 | $127.63 | $2,758,594.82 | 616,643 | |
| 8/17/2020 | Sell | 16,485 | $128.18 | $2,113,047.30 | 616,643 | |
| 8/14/2020 | Sell | 16,857 | $127.07 | $2,142,018.99 | 616,643 | |
| 8/12/2020 | Sell | 21,916 | $127.21 | $2,787,934.36 | 616,643 | |
| 8/10/2020 | Sell | 48,148 | $120.79 | $5,815,796.92 | 616,643 | |
| 8/4/2020 | Sell | 45,488 | $124.43 | $5,660,071.84 | 616,643 | |
| 7/31/2020 | Sell | 39,622 | $118.17 | $4,682,131.74 | 616,643 | |
| 7/29/2020 | Sell | 47,106 | $123.99 | $5,840,672.94 | 616,643 | |
| 7/27/2020 | Sell | 29,019 | $110.43 | $3,204,568.17 | 616,643 | |
| 7/24/2020 | Sell | 66,123 | $108.87 | $7,198,811.01 | 616,643 | |
| 7/22/2020 | Sell | 35,878 | $109.99 | $3,946,221.22 | 616,643 | |
| 7/20/2020 | Sell | 17,735 | $105.47 | $1,870,510.45 | 616,643 | |
| 7/17/2020 | Sell | 19,309 | $105.32 | $2,033,623.88 | 616,643 | |
| 7/15/2020 | Sell | 28,700 | $104.90 | $3,010,630.00 | 616,643 | |
| 7/13/2020 | Sell | 8,582 | $100.40 | $861,632.80 | | |
| 2/4/2019 | Sell | 18,920 | $66.54 | $1,258,936.80 | 603,702 | |
| 2/1/2019 | Sell | 84,093 | $65.54 | $5,511,455.22 | 603,702 | |
| 1/30/2019 | Sell | 102,828 | $63.22 | $6,500,786.16 | 603,702 | |
| 1/28/2019 | Sell | 4,221 | $61.04 | $257,649.84 | 603,702 | |
| 1/24/2019 | Sell | 3,501 | $61.14 | $214,051.14 | 603,702 | |
| 1/22/2019 | Sell | 9,936 | $61.10 | $607,089.60 | 603,702 | |
| 1/17/2019 | Sell | 8,760 | $61.17 | $535,849.20 | 603,702 | |
| 1/15/2019 | Sell | 600 | $61.00 | $36,600.00 | 603,702 | |
| 9/27/2018 | Sell | 46,778 | $58.96 | $2,758,030.88 | 351,851 | |
| 9/25/2018 | Sell | 38,640 | $58.36 | $2,255,030.40 | 351,851 | |
| 9/20/2018 | Sell | 114,983 | $59.31 | $6,819,641.73 | 351,851 | |
| 8/6/2018 | Sell | 731,460 | $59.26 | $43,346,319.60 | 849,621 | |
| 8/2/2018 | Sell | 371,795 | $59.20 | $22,010,264.00 | 849,621 | |
| 8/18/2016 | Buy | 10,000 | $27.98 | $279,800.00 | 1,221,416 | |
| 8/16/2016 | Buy | 869,565 | $23.00 | $19,999,995.00 | 1,221,416 | |
Medpace Company Overview
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Read More
Today's Range
Now:
$182.49
Low: $180.00
High: $184.16
50 Day Range
MA:
$154.24
Low: $132.27
High: $182.30
2 Week Range
Now:
$182.49
Low: $126.94
High: $231.00
Volume
181,991 shs
Average Volume
341,183 shs
Market Capitalization
$5.66 billion
P/E Ratio
31.68
Dividend Yield
N/A
Beta
1.43
